![Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease](https://mma.prnewswire.com/media/686979/Teva_Canada_Limited_Teva_Canada_Announces_the_Launch_of_Teva_Cyc.jpg)
Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease
![Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease](https://mma.prnewswire.com/media/687688/Teva_Canada_Limited_Teva_Canada_Announces_the_Launch_of_Teva_Cyc.jpg?p=facebook)
Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease
![Allergan, Inc. v. Teva Pharms.: Federal Court Invalidates Allergan Patents as Obvious - Harvard Journal of Law & Technology Allergan, Inc. v. Teva Pharms.: Federal Court Invalidates Allergan Patents as Obvious - Harvard Journal of Law & Technology](https://jolt.law.harvard.edu/assets/digestImages/2016/_digestHeader/27075209-Patented-blue-grunge-retro-style-isolated-seal-Stock-Photo-patent.jpg)